Cargando…
Dabigatran: patient management in specific clinical settings
Dabigatran, a direct thrombin inhibitor, is licensed for the prevention of venous thromboembolism after knee and hip replacement, the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for the treatment of acute venous thromboembolism. As dabigatran has...
Autores principales: | Kyrle, Paul Alexander, Binder, Konrad, Eichinger, Sabine, Függer, Reinhold, Gollackner, Bernd, Hiesmayr, J. Michael, Huber, Kurt, Lang, Wielfried, Perger, Peter, Quehenberger, Peter, Roithinger, Franz X., Schmaldienst, Sabine, Weltermann, Ansgar, Domanovits, Hans |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165862/ https://www.ncbi.nlm.nih.gov/pubmed/25138549 http://dx.doi.org/10.1007/s00508-014-0581-x |
Ejemplares similares
-
Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management
por: Weltermann, A., et al.
Publicado: (2012) -
Management of dabigatran-induced bleeding: expert statement
por: Fries, Dietmar, et al.
Publicado: (2013) -
Absorption of Direct Oral Anticoagulants in Cancer Patients after Gastrectomy
por: Puhr, Hannah C., et al.
Publicado: (2022) -
d‐Dimer Levels Over Time and the Risk of Recurrent Venous Thromboembolism: An Update of the Vienna Prediction Model
por: Eichinger, Sabine, et al.
Publicado: (2014) -
Prediction of Recurrent Venous Thromboembolism by Clot Lysis Time: A Prospective Cohort Study
por: Traby, Ludwig, et al.
Publicado: (2012)